Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $473.00. The company’s shares closed yesterday ...